Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    Urokinase-type plasminogen activator receptor
Show Display Options
Rank Status Study
1 Recruiting Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Abiraterone;   Drug: Prednisolone
2 Unknown  Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis
Condition: Neonatal Sepsis
3 Completed Dietary Seaweed and Early Breast Cancer: A Randomized Trial
Condition: Seaweed Associated Changes in Healthy Subjects
Intervention: Other: Seaweed
4 Completed Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
Conditions: Breast Cancer;   Prostate Cancer;   Urinary Bladder Cancer
Intervention: Other: Injection of 64Cu-DOTA-AE105
5 Recruiting Role of SLURP-1 in Melanoma and Melanoma Stem Cells
Condition: Melanoma;
6 Recruiting A Prospective Controlled Follow-up of Serum suPAR in the CsA-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis (FSGS)
Condition: FSGS
7 Active, not recruiting Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Conditions: Prostate Cancer;   Elevated Prostate Specific Antigen (PSA)
Intervention: Other: serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
8 Recruiting Clinical Evaluation of Novel Biomarkers in Patients With Septicemia
Conditions: Sepsis;   Bacteremia;   Fungemia

Indicates status has not been verified in more than two years